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Abstract 
Background: Contemporary guidelines recommend angiotensin‑converting‑enzyme inhibitors (ACEi) or angio‑
tensin‑receptor blockers (ARB) for hypertensive patients with diabetes. However, there is limited data to evaluate 
the comparison between ACEi and ARB on end stage renal disease (ESRD) and major adverse cardiovascular events 
(MACE), in Asian diabetic patients.
Methods: We used the Taiwan Longitudinal Cohort of Diabetes Patients Database to perform a population‑based 
dynamic cohort study. The comparison between ACEi and ARB on ESRD and MACE in diabetic patients was examined 
using the propensity score weighting method. We followed these patients until the occurrence of first study out‑
comes or end date of the study, whichever came first.
Results: There were 6898 and 12,758 patients in ACEi and ARB groups, respectively. The mean follow‑up period was 
about 3.5 years in ESRD and 2.5 years in MACE. The incidence of ESRD was 0.44 % and 0.63 % per person‑years in the 
ACEi and ARB group, respectively. The risk of ESRD was lower in the ACEi group than the ARB group [hazard ratio (HR) 
0.69; 95 % confidence interval (CI) 0.54–0.88, P = 0.0025]. Among those without chronic kidney disease (CKD), the 
incidence of ESRD was 0.30 % and 0.37 % per person‑years in the ACEi and ARB group, respectively. ACEi was similar to 
ARB in preventing ESRD for those without CKD (P = 0.11). Among those with CKD, the incidence of ESRD was 1.39 % 
and 2.34 % per person‑years in the ACEi and ARB group, respectively. The ACEi group had a lower risk of ESRD than the 
ARB group (HR 0.61; 95 % CI 0.42–0.88, P = 0.008). The incidence of MACE was 9.33 % and 9.62 % per person‑years in 
the ACEi and ARB group, respectively. There was no significant difference in the composite MACE outcome between 
the two groups (P = 0.42), but the ACEi group was associated with a higher risk of stroke than the ARB group (HR 1.12; 
95 % CI 1.02–1.24, P = 0.02).
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Background
Diabetes mellitus (DM) is a global health problem and 
a major cause of cardiovascular disease and end-stage 
renal disease (ESRD) [1, 2]. According to current guide-
lines [1, 3], angiotensin-converting enzyme inhibitors 
(ACEi) and angiotensin receptor blockers (ARB) are rec-
ommended for the treatment of hypertension, and espe-
cially for diabetic patients. Both drugs block angiotensin 
II, however ACEi are characterized by a decrease in the 
degradation of bradykinin leading to a release of nitric 
oxide and prostaglandins resulting in additional vasodil-
atation. The differences in the modes of action between 
ACEi and ARB may have clinical implications for dia-
betic patients [4, 5]. A recently published meta-analysis 
[6] showed that ACEi were associated with a significant 
reduction (14  %) in major cardiovascular events, but 
that ARB had no benefit on these outcomes. In these 
patients, management of cardiovascular risk factors and 
careful monitoring eGFR may represent opportunities to 
reduce the risk of major adverse cardiovascular events 
(MACE) [7]. In addition, these two agents have been 
reported to be beneficial in delaying the progression of 
kidney disease in patients with non-dialysis-dependent 
chronic kidney disease (CKD) [8–10]. However, studies 
comparing ACEi and ARB with regards to renoprotec-
tive effects are limited.
Cough occurs in 5–20 % of patients treated with ACEi. 
The mechanism may involve accumulation of prosta-
glandins, kinins, or substance P, as both bradykinin and 
substance P are degraded by ACE [11]. Furthermore, 
the incidence of discontinuing ACEi due to cough has 
been reported to be up to 30 % in Asian patients [12, 13]. 
Therefore, it is important to have a comparison of the 
efficacy of these two classes of drugs in Asian diabetic 
patients. Given the uncertainty surrounding the effect of 
ACEi/ARB, we performed a retrospective, population-
based dynamic cohort study to compare the efficacy 




The National Health Insurance (NHI) program, a com-
pulsory universal health care system in Taiwan, was 
launched in 1995 and currently covers 23.72 million 
enrollees or about 99 % of the population. The National 
Health Research Institute (NHRI) is responsible for 
managing and maintaining all insurance claims data, 
and various datasets are released for research purposes 
after thorough review and after all personal information 
has been encrypted. Hence, informed consent was not 
required for this study. The study protocol conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki 
and was approval by the Institutional Review Board of the 
Chang Gung Medical Foundation, Taiwan (103-7871C).
Data from the Longitudinal Cohort of Diabetes Patients 
(LHDB) released by the NHRI were used for this study. In 
LHDB, patients who were first diagnosed with DM from 
1999 to 2010 were eligible for this study, if they: (1) had at 
least one hospitalization with DM as one of the discharge 
codes (A-code A181 before 2000 or ICD-9-CM code 250 
after 2000) or used DM medications (Additional file  1); 
(2) had at least two outpatient visits due to DM in the 
same year; (3) had no hospitalizations or outpatient visits 
due to DM from 1996 to 1998; (4) were over 20 years of 
age. Due to the restriction set by the NHRI of releasing 
data no more than 10 % of the total population, an annual 
total of 120,000 eligible patients from 1999 to 2010 were 
randomly selected, and their original claims data includ-
ing admissions, outpatient visits, and medications were 
recorded in the LHDB. The LHDB included data before 
a diagnosis of DM and treatment for patients with and 
without DM. The LHDB has been tested and confirmed 
by other studies to be representative of Taiwanese 
patients with DM [14–18]. In this study, ACEi and ARB 
were listed in the supplement. Patients in LHDB who 
had been prescribed ACEi or ARB before the first diag-
nosis of DM, or who had been prescribed neither ACEi 
nor ARB were excluded. ACEi users were those who took 
ACEi but not ARB. The ARB group were those who took 
ARB but not ACEi. The index date was defined as the cal-
endar date of a first prescription of ACEi or ARB. Our 
selection further excluded if (1) the year of their first pre-
scription was before 1996, or (2) they were younger than 
age 20 years of age on index date, or (3) they had ESRD 
before index date, or (4) they did not had hypertension 
before index date, or (5) cover rate less than 70  %. The 
follow-up period was from the index date until either the 
date of new onset of MACE or ESRD (when treated as 
an outcome variable), or 31 December 2011, whichever 
Conclusions: ACEi compared with ARB was associated with a lower incidence of ESRD, especially in those with CKD. 
Though ACEi and ARB had a similar risk of composite MACE outcome, ACEi had a slightly higher incidence of stroke 
than ARB, among the Asian diabetic patients.
Keywords: Angiotensin converting enzyme inhibitors, Angiotensin receptor blockers, Diabetes mellitus, Major 
adverse cardiovascular events, End‑stage renal disease
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came first (Fig. 1). Note that the nature of LHDB and this 
study design is qualified as a dynamic cohort, in which 
eligible participants were recruited when newly diag-
nosed patients appeared during the study. The advantage 
of a dynamic cohort is that the number of participants 
does not decline over time, and that aging of the study 
participants over time does not weaken the study.
A patient is considered to have reached the end points 
of the study, the occurrence of MACE, if he or she has 
bee diagnosed with one of the codes: International Clas-
sification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) codes as follows: myocardial infarction 
(410), congestive heart failure (428), stroke (430–437), 
malignant dysrhythmia (426.0, 426.12–426.13, 426.51–
426.52, 426.54, 427.1, 427.4, 427.41–427.42, 427.5), 
cardiogenic shock (785.51); or procedure codes of 
the Taiwan NHI for percutaneous coronary interven-
tion (PCI) (33076A, 33076B, 33077A, 33077B, 33078A, 
33078B), coronary artery bypass surgery (CABG) 
(68023A, 68023B, 68024A, 68024B, 68025A, 68025B), 
and thrombolysis therapy (B016526248, K000743248, 
K000744238) [19]. A previous MACE is defined as a hos-
pitalization due to MACE before the index date. A new 
MACE is defined as a hospitalization with MACE as the 
primary diagnosis 14 days after the index date.
Patients with chronic kidney disease are defined as 
those who were diagnosed with ICD9-CM codes 580–
589 at least twice at an outpatient clinic or a discharge. 
Patients with hyperlipidemia are defined as those who 
were diagnosed with ICD9-CM code 272 or A182 at least 
twice at an outpatient clinic or a discharge.
Patients with ESRD requiring chronic renal replace-
ment therapy are eligible for a catastrophic illness cer-
tificate in Taiwan. Patients with a catastrophic illness 
certificate are entitled to a waiver for medical co-pay-
ment. Diagnostic information is sent to the insurance 
administration for a review by a panel of commissioned 
experts to review the diagnosis and approve the waiver. 
Consequently, ESRD is defined as patients with a cata-
strophic illness certificate for ESRD (ICD-9-CM code: 
585).
Statistical analysis
We use the propensity score method to compare 
between ACEi and ARB on the ESRD and MACE in DM 
patients to eliminate the effects of unbalanced demo-
graphic and comorbid medical disorders at index date 
for observational data. The propensity score was the pre-
dicted probability of being in ACEi group derived from 
the fitted logistic regression, in which group status was 
regressed on covariates at index date (Table  1). Inverse 
probability of treatment weights (IPTWs) using the pro-
pensity scores was then applied to balance covariates 
across the two study groups. The standardized mean 
difference (SMD) rather than using statistical testing 
was made to examine the balance of covariates at index 
date between the two study groups, because balance is a 
property of the sample and not of an underlying popula-
tion. The absolute value of SMD ≤  0.1 indicates a neg-
ligible difference in covariates between the two study 
groups [20]. In time-to-event analyses, incident rate, 
crude hazard ratio (log-rank test) and adjusted haz-
ard ratio (Cox’s proportional hazard model) were esti-
mated, accounting for the weighted nature of two study 
groups with robust variance estimation [21]. Statistical 
significance was defined as a P value less than 0.05. All 
statistical analyses were performed using SAS 9.2 (SAS 
Institute Inc., Cary, NC, USA).
Results
The demographic characteristics and comorbid medical 
disorders at the index date are shown in Table  1. There 
were 6898 patients in ACEi and 12,758 patients in ARB 
groups, respectively. On average, patients were pre-
scribed either ACEi or ARB 3 years after being diagnosed 
with DM. The mean age at the first prescription of either 
ACEi or ARB was 61.5  ±  13.0 and 62.4  ±  12.8  years, 
respectively. Approximately half (54.5  %) had hyperlipi-
demia, 13.5 % had CKD, 12.7 % had stroke and 5 % had 
myocardial infarction (MI) or PCI. A history of conges-
tive heart failure, cardiogenic shock, CABG, and throm-
bolysis therapy were not common (from 0.25 to 4.51 %). 
After propensity score weighting, the age, gender and 
comorbid medical disorders were comparable with 
Fig. 1 Flowchart of subject selection. LHDB longitudinal cohort of 
diabetes patients, DM diabetes mellitus, ACEi angiotensin converting 
enzyme inhibitors, ARB angiotensin receptor blockers, ESRD end stage 
renal disease, MACE major adverse cardiovascular events
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absolute values of standardized mean difference <0.1 
between the two study groups.
During 26,809 person-years with a mean follow-up 
of 3.9 years in the ACEi group and 41,292 person-years 
with a mean follow-up of 3.2 years in the ARB group, the 
incidence (person-years) of ESRD was 0.44 % in the ACEi 
group and 0.63  % in the ARB group (Table  2). Figure  2 
displays the Kaplan–Meier curves of ESRD-free rate 
among the ACEi and ARB group. The ACEi group had a 
lower incidence of ESRD than the ARB group (HR 0.69; 
95 % CI 0.54–0.88, P = 0.0025). 
Furthermore, we evaluated the effect of CKD on the 
incidence of ESRD. There were 5966 and 10,623 patients 
without CKD in ACEi and ARB group, respectively. 
Among those without CKD, the mean age at the first pre-
scription of either ACEi or ARB was 60.8 and 60.6 years, 
respectively. Approximately half (53.8  %) had hyperlipi-
demia, 12.2 % had stroke and 5 % had MI or PCI. A his-
tory of congestive heart failure, cardiogenic shock, CABG 
and thrombolysis therapy were not common (from 0.3 to 
4.0 %). During 23,353 person-years with a mean follow-
up of 3.9  years in ACEi group and 34,928 person-years 
with a mean follow-up of 3.3  years in ARB group, the 
incidence (person-years) of ESRD was 0.30 and 0.37 % in 
the ACEi and ARB group, respectively (Table  3). There 
were no significant differences in ESRD between the two 
groups (HR 0.76; 95 % CI 0.55–1.06, P = 0.11) (Fig. 3). 
There were 932 and 2135 patients with CKD in the ACEi 
and ARB group, respectively. The mean age was 65.5 years 
in the ACEi group and 65.2  years in the ARB group. 
Approximately half (59 %) had hyperlipidemia, 16.2 % had 
stroke, 8.1 % had CHF and 5.2 % had MI or PCI. A history 
of cardiogenic shock, CABG and thrombolysis therapy 
were not common (from 0 to 0.7  %). Among those with 
CKD, during 3457 person-years with a mean follow-up of 
3.7  years in the ACEi group and 6364 person-years with 
a mean follow-up of 3.0 years in the ARB group, the inci-
dence rate (person-years) of ESRD was 1.39 and 2.34 % in 
the ACEi and ARB group, respectively (Table 3). The ACEi 
group had a lower rate of the ESRD than with ARB group 
(HR 0.61; 95 % CI 0.42–0.88, P = 0.008) (Fig. 3).
During 19,203 person-years with a mean follow-up 
of 2.8  years in the ACEi group and 30,389 person-years 
with a mean follow-up of 2.4 years in the ARB group, the 
incidence rate (person-years) of any MACE was 9.33 and 
9.62 % in the ACEi and ARB groups, respectively (Table 2). 
Table 1 The demographic and comorbid medical disorders at  index date, before and after propensity score weighting, 
among  hypertensive and  diabetic patients who were prescribed with  either angiotensin-converting enzyme inhibitors 
(ACEi) or angiotensin receptor blockers (ARB)
DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MI myocardial infarction, PCI percutaneous coronary 
intevention, CABG coronary artery bypass graft surgery
a Index date was the date first prescribed either ACEi or ARB
Propensity score weighting
Before After
ACEi (n = 6898) ARB (n = 12,758) Standardized  
mean difference
ACEi (n = 6898) ARB (n = 12,758) Standardized 
mean difference
Duration from DM to 
index datea (years)
3.07 ± 3.15 3.69 ± 3.33 −0.1931 3.17 ± 3.15 3.08 ± 2.26 −0.0032
Age (years) (mean ± SD) 61.5 ± 13.0 62.4 ± 12.8 −0.0711 61.5 ± 13.0 61.3 ± 9.7 0.0183
Age group 0.0944 0.0053
 20–49 (%) 20.9 17.2 20.9 21.0
 50–64 (%) 39.4 40.3 39.4 39.5
 65+ (%) 39.7 42.4 39.7 39.5
Male sex 59.5 % 53.1 % 0.1271 59.5 % 59.5 % −0.0016
Congestive heart failure 4.51 % 4.85 % −0.0163 4.51 % 4.51 % −0.0000
Stroke 12.73 % 14.70 % −0.0572 12.73 % 12.73 % −0.0000
Malignant dysrhythmia 0.45 % 0.49 % −0.0054 0.45 % 0.45 % 0.0004
Cardiogenic shock 0.32 % 0.23 % 0.0176 0.32 % 0.33 % −0.0025
MI/PCI 5.00 % 4.56 % 0.0206 5.00 % 4.98 % 0.0010
CABG 0.46 % 0.60 % −0.0192 0.46 % 0.46 % 0.0012
Thrombolysis therapy 0.25 % 0.24 % 0.0023 0.25 % 0.24 % 0.0018
Hyperlipidemia 54.54 % 59.81 % −0.1066 54.54 % 54.68 % −0.0029
Chronic kidney disease 13.51 % 16.73 % −0.0901 13.51 % 13.51 % 0.0001
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Figure 4 displays the Kaplan–Meier curves of MACE free 
rate for the two study groups. There were no significant 
differences in MACE between the two groups (HR 1.03; 
95 % CI 0.96–1.10, P = 0.42). Stroke, MI or PCI and con-
gestive heart failure were the most common MACE in 
both the ACEi and ARB groups, with incidence (person-
years) of 3.78/3.56, 1.77/2.19, and 1.48/1.51 %, respectively. 
Note that the ACEi group had a higher incidence of stroke 
than the ARB group (HR 1.12; 95 % CI 1.02–1.24, P = 0.02) 
(Table  2). Figure  5 displays the Kaplan–Meier curves of 
stroke- free rate among the ACEi and ARB group. 
Discussion
In this study, we compared the long-term impact of ACEi 
and ARB in Asian diabetic patients, using a population-
based dynamic cohort study design and propensity score 
weighting method. Our results demonstrated that ACEi 
compared with ARB was associated with a lower incidence 
of the progression to ESRD in diabetic patients, especially 
in the patients with CKD. In addition, though ACEi and 
ARB had a similar incidence of the composite MACE out-
come, ARB had a lower incidence of the stroke than ACEi.
Clinical studies of ACEi and ARB have shown that they 
reduce albuminuria and the loss of glomerular filtration 
rate and the need for dialysis in those with advanced renal 
disease [22]. Data from the ONTARGET trial [23], which 
focused on diabetic patients showed that the effect of tel-
misartan on dialysis was similar to ramipril with rates of 
hemodialysis of 0.6 and 0.56 %, respectively (P = 0.747). 
A retrospective cohort study, using Veterans Affairs data-
bases showed that ACEIs are associated with lower ESRD 
development in diabetic patients compared with ARB 
(Odds ratio 0.10; 95  % CI 0.04–0.21, P  =  0.02) [24]. In 
this study, focused on diabetic patients with hyperten-
sion, we demonstrated that ACEi was superior to ARB 
in preventing ESRD development (HR 0.69; 95  % CI 
0.54–0.88, P  =  0.0025). Lacourciere et  al. demonstrated 
that among diabetic patients with normal glomerular fil-
tration rate (GFR), the rate of decline in GFR with 1 year 
follow up is similar between patients taking either ACEi 
or ARB [25]. Our study with longer follow-up duration 
(mean 3.5 years) also showed the ACEi/ARB have similar 
effect in progression to ESRD among the diabetic patients 
without CKD. In addition, among the patients with CKD, 
our study demonstrated that ACEi was associated with 
a lower risk of ESRD than ARB (HR 0.61, 95 % CI 0.42–
0.88, P = 0.008). We saw that ACEi with a better renopro-
tective effect than ARB, primary from these with CKD. 
There are two important differences between ACEi and 
ARB (angiotensin II type I antagonists). The first is the 
Table 2 Incidence (per 100 person-years) of outcomes among the ACEi and ARB users after propensity score weighting
ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CI confidence interval, MACE major adverse cardiovascular disease, MI myocardial 
infarction, CHF cogestive heart failure, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery, ESRD end stage renal disease
a MACE = CHF or stroke or malignant dysrhythmia or cardiogenic shock or MI or PCI or CABG or thrombolysis therapy
Incidence (95 % CI) Hazard ratio (95 % CI)
ACEi (n = 6898) ARB (n = 12,758) ACEi vs. ARB P value
MACE
 Any MACEa 9.33 (8.90−9.76) 9.62 (9.16−10.08) 1.03 (0.96−1.10) 0.4244
 Cogestive heart failure 1.48 (1.33−1.63) 1.51 (1.35−1.67) 1.06 (0.91−1.22) 0.4538
 Stroke 3.78 (3.53−4.03) 3.56 (3.31−3.82) 1.12 (1.02−1.24) 0.0230
 Malignant dysrhythmia 0.16 (0.12−0.21) 0.15 (0.10−0.20) 1.14 (0.73−1.77) 0.5571
 Cardiogenic shock 0.03 (0.01−0.06) 0.04 (0.02−0.07) 0.81 (0.31−2.07) 0.6547
 MI or PCI 1.77 (1.61−1.93) 2.19 (2.00−2.39) 0.89 (0.78−1.01) 0.0646
 CABG 0.18 (0.13−0.23) 0.22 (0.16−0.28) 0.89 (0.60−1.31) 0.5438
 Thrombolysis therapy 0.00 (0.00−0.02) 0.02 (0.01−0.05) 0.19 (0.02−1.66) 0.1339
 ESRD 0.44 (0.36−0.52) 0.63 (0.53−0.73) 0.69 (0.54−0.88) 0.0025
Fig. 2 Overall end stage renal disease free rates for ACEi and ARB 
users after propensity score weighting. ACEi angiotensin converting 
enzyme inhibitors, ARB angiotensin receptor blockers, ESRD end stage 
renal disease
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Table 3 The demographic and comorbid medical disorders at index date after propensity score weighting among hyper-
tensive and diabetic patients who were prescribed with either angiotensin-converting enzyme inhibitors (ACEi) or angio-
tensin receptor blockers (ARB) stratified by chronic kidney disease or not
DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CKD chronic kidney diseases, MI myocardial infarction, PCI 
percutaneous coronary intevention, CABG coronary artery bypass graft surgery
a Incidence per 100 person-years
Propensity score weighting
With CKD Without CKD
ACEi (n = 932) ARB (n = 2135) Standardized  
mean difference
ACEi (n = 5966) ARB (n = 10,623) Standardized mean 
difference
Duration from DM to 
index date (years)
3.50 ± 3.33 3.52 ± 2.09 −0.0049 3.00 ± 3.11 3.01 ± 2.29 −0.0035
Age (years) (mean ± SD) 65.5 ± 13.3 65.2 ± 8.8 0.0276 60.8 ± 12.9 60.6 ± 9.8 0.0175
Age group (years) 0.0123 0.0049
 20–49 (%) 14.70 15.06 21.81 21.92
 50–64 (%) 32.08 32.25 40.56 40.69
 65+ (%) 53.22 52.69 37.63 37.39
Male sex 59.12 % 59.21 % −0.0019 59.52 % 59.62 % −0.0019
Congestive heart failure 8.05 % 8.15 % −0.0039 3.96 % 3.94 % 0.0006
Stroke 16.20 % 16.15 % 0.0014 12.19 % 12.16 % 0.0007
Malignant dysrhythmia 0.21 % 0.21 % 0.0014 0.49 % 0.48 % 0.0011
Cardiogenic shock 0.64 % 0.73 % −0.0102 0.27 % 0.27 % −0.0011
MI/PCI 5.15 % 5.08 % 0.0030 4.98 % 4.96 % 0.0008
CABG 0.11 % 0.11 % −0.0010 0.52 % 0.51 % 0.0008
Thrombolysis therapy 0.00 % 0.00 % −0.0002 0.28 % 0.28 % 0.0012
Hyperlipidemia 59.44 % 59.86 % −0.0085 53.77 % 53.77 % −0.0017
Incidence of ESRDa 1.39 2.34 0.30 0.37
(95 % CI) (1.00−1.78) (1.80−2.89) (0.23−0.37) (0.29−0.46)
Fig. 3 End stage renal disease free rates stratified by chronic kidney 
disease or not for ACEi and ARB users after propensity score weight‑
ing. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin 
receptor blockers, ESRD end stage renal disease, CKD chronic kidney 
disease
Fig. 4 Overall major adverse‑cardiovascular‑events free rates for ACEi 
and ARB users after propensity score weighting. ACEi angiotensin 
converting enzyme inhibitors, ARB angiotensin receptor blockers, 
MACE major adverse cardiovascular events
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blockade of bradykinin degradation by ACEi and the sec-
ond is the supraphysiologic activation of the Angiotensin 
II type 2 receptor (AT2) when ARB (AT1 antagonists) are 
administered [26]. AT2 receptor plays a counterregulatory 
protective role mediated via bradykinin and nitric oxide 
against the antinatriuretic and pressor actions of angio-
tensin II [27]. These mechanisms may explain why ACEi 
has better renoprotection than ARB. Some studies have 
suggested that dual blockage of renin–angiotensin system 
may provide additive benefit in diabetic nephropathy, but 
further studies are needed to validate such therapy, which 
should be used with caution [28].
In our study, the incident rates of cardiovascular 
comorbidities including myocardial infarction, conges-
tive heart failure, PCI and stroke were relatively lower, 
as compared with the HOPE [29], TRANSCEND [30], 
or ONTARGET [31] studies. The ONTARGET study 
(Asian population 13.8 %, 1200 patients) compared the 
ACEi (ramipril) and the ARB (telmisartan) in patients 
with vascular disease or high-risk diabetes (37  %), and 
found that telmisartan was equivalent to ramipril in 
reducing mortality and morbidity from cardiovascular 
causes. We also found that treatment with ACEi and 
ARB had a similar incidence of the composite MACE 
outcome in Asian diabetic patients. On the other hand, 
we found that among diabetic patients, ACEi has a 
slightly higher risk of stroke than ARB (HR 1.12; 95  % 
CI 1.02–1.24, P  =  0.023). In other words, our study 
demonstrated that ARB has a slightly better protective 
effect on stroke than ACEi among the diabetic patients. 
A meta-analysis [32], which did not focus on the dia-
betic patients, also showed that ARB was more protec-
tive than ACEi on the risk of stroke (odds ratio 0.92; 
95 % CI:0.85–0.99, P = 0.037).
There are several limitations to this study. First, nearly 
all hospitals/clinics are linked to the National Health 
Insurance (NHI) program, which covered over 99  % of 
the population covered by the program during the study 
period. However, it is possible that we were not able to 
assess some cases of MACE. Second, several impor-
tant clinical parameters are not available in the NHI 
claims database, including clinical/imaging informa-
tion, severity of MACE, smoking history, albuminuria, 
LDL-cholesterol, and creatinine level. Third, the benefit 
of antiplatelet agents in primary prevention for cardio-
vascular events is still under debate, so we do not exam-
ine the effect of antiplatelet agents in MACE and ESRD. 
[33].
In conclusion, among Asian diabetic patients, ACEi 
appeared to have a lower risk of ESRD development than 
ARB, especially in those with chronic kidney disease. 
Despite the similar incidence of the composite MACE 
outcome, ARB was slightly more protective than ACEi on 
the risk of stroke.
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